Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982486 | 0.91 | KDM4E (0.58) | KEAP1NFE2L2HRH3KDM4EALDH1A1 | |
| SCHEMBL11715528 | 0.90 | LTA4H (0.63) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL20982689 | 0.90 | KDM4E (0.52) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL20982799 | 0.89 | KDM4E (0.59) | KEAP1NFE2L2HRH3KDM4EALDH1A1 | |
| SCHEMBL11713528 | 0.89 | LTA4H (0.58) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL7353689 | 0.86 | KEAP1 (0.53) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL310630 | 0.86 | KEAP1 (0.53) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL30343866 | 0.86 | KEAP1 (0.53) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL3543706 | 0.84 | KEAP1 (0.51) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 | |
| SCHEMBL2688417 | 0.84 | KEAP1 (0.51) | KEAP1NFE2L2HRH3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-0249239-B1 | Process for the formation of direct positive images | FUJI PHOTO FILM CO LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-4954427-A | Development of light-sensitive material in the presence of a nucleating agent and a nuceation accelerator | FUJI PHOTO FILM CO., LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4933265-A | NUCLEATION PROMOTER | FUJI PHOTO FILM CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4886738-A | COLOR REVERSAL MATERIAL WITH IMPROVED PUSH DEVELOPABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0249239-A2 | Process for the formation of direct positive images | FUJI PHOTO FILM CO., LTD. (JP) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | KEAP1 1695/4885NFE2L2 1027/4885HRH3 1553/4885 |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | KEAP1 1497/4885NFE2L2 1740/4885HRH3 389/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | KEAP1 1497/4885NFE2L2 1740/4885HRH3 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.